Otologic Pharmaceutics · Small Molecule · Phase 1
CompletedTherapeutic
Population
Adults · 18–55 years
Hazardous noise or blast exposure
Evidence
company
Confidence
89%
Indications
Hearing LossSensorineural Hearing LossNoise-Induced Hearing LossTinnitus
